Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
16
×
boston blog main
boston top stories
san francisco blog main
san francisco top stories
biotech
deals
new york blog main
new york top stories
gene therapy
national
boston
san diego blog main
san diego top stories
alnylam pharmaceuticals
clinical trials
hemophilia
pfizer
spark therapeutics
boulder/denver blog main
boulder/denver top stories
cancer
crispr
detroit blog main
detroit top stories
fda
gene editing
indiana blog main
indiana top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
roche
sangamo therapeutics
seattle blog main
seattle top stories
startups
texas blog main
What
gene
16
×
therapy
medicine
bio
drug
crispr
editing
roundup
therapeutics
fda
medicines
race
rna
advanced
approval
aren’t
car
cas
cells
cutting
deal
disease
edge
help
human
interference
long
market
morning
moves
past
patients
prices
protein
roche
sangamo
science
years
access
age
Language
unset
Current search:
gene
×
" national top stories "
×
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M